Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GSK3326595||EPZ015938||GSK3326595 inhibits PRMT5, potentially resulting in decreased SmD3 methylation and reduced tumor growth (PMID: 28067760, PMID: 25915199).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02783300||Phase I||GSK3326595||Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL)||Recruiting|
|NCT03614728||Phase Ib/II||Azacitidine + GSK3326595 GSK3326595||Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)||Recruiting|